Ultrasound therapy for lateral epicondylitis. A double blind randomised placebo controlled trial

Submission date Recruitment status Prospectively registered 12/09/2003 No longer recruiting [] Protocol [] Statistical analysis plan Registration date Overall study status 12/09/2003 Completed [X] Results [] Individual participant data Last Edited Condition category 06/12/2013 Musculoskeletal Diseases

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Cathy Speed

Contact details

Box No 204
Department of Rheumatology
Addenbrooke's NHS Trust
Hills Road
Cambridge
United Kingdom
CB2 2QQ

Additional identifiers

Protocol serial number N0544103837

Study information

Scientific Title

Study objectives

Ultrasound therapy for lateral epicondylitis

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Study type(s)

Not Specified

Health condition(s) or problem(s) studied

Lateral epicondylitis (tennis elbow)

Interventions

To evaluate the effects of ultrasound in the treatment of lateral epicondylitis. Adult subjects with lateral epicondylitis will be randomised to receive either ultrasound (US) or sham (S) therapy. In the US group pulsed ultrasound will be delivered at a standardised dosage, initially five times weekly for 3 weeks, then three times weekly for 3 weeks. A single machine will be used and calibrated twice daily. The patient, assessor and treating clinician will be blinded. Outcome measures will be recorded at 6 weeks and at 9 months from baseline. These will include a forearm evaluation score and pain (primary measures), grip strength, flexibility, inflammation (thermographic score), quality of life and general health status, a summary item of status of the injury and a follow up transition item.

Intervention Type

Other

Phase

Not Specified

Primary outcome(s)

Not provided at time of registration

Key secondary outcome(s))

Not provided at time of registration

Completion date

11/09/2003

Eligibility

Key inclusion criteria

200 18-75 year olds (PROJ)

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Upper age limit

75 years

Sex

Αll

Key exclusion criteria

Does not match inclusion criteria

Date of first enrolment

11/09/2000

Date of final enrolment

11/09/2003

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

Box No 204

Cambridge United Kingdom CB2 2QQ

Sponsor information

Organisation

Funder(s)

Funder type

Other

Funder Name

Cambridge Consortium - Addenbrooke's (UK)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/05/2006		Yes	No